{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"Proportion of patients with a complete response after 12 cycles of therapy. A complete response (CR) is defined as having resolution of WM related symptoms, normalization of serum IgM levels with complete disappearance of IgM paraprotein by immunofixation, and resolution of any adenopathy or splenomegaly.","groups":[{"description":"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.\n\n* Ibrutinib will be administered at a predetermined dose, once daily for 28 days\n* TLS Prophylaxis (Treatment to reduce risk of tumor lysis syndrome) prior to first dose of venetoclax (and for at least the first 2 weeks of treatment)\n* Venetoclax Cycle 2-24. PO daily, predetermined dosage ramp up during cycle 2.\n\nIBRUTINIB: Ibrutinib Cycle 1-24 will be administered at a predetermined dose, once daily for 28 days\n\nVenetoclax: Venetoclax Cycle 2-24 will be administered daily for 28 days. Predetermined dosage ramp up schedule during cycle 2.","id":"OG000","title":"Ibrutinib and Venetoclax"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"12 Cycles (28 day cycle)","title":"Number of Participants With Complete Response (CR) After 12 Cycles","type":"SECONDARY","unitOfMeasure":"Participants"}